DMAC vs GS · $157.4M cap vs P/E 20, $324.25B cap
DiaMedica Therapeutics Inc (DMAC) versus Goldman Sachs Group Inc (GS) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David Solomon.
DMAC does not have a complete income-statement cache yet.
GS does not have a complete income-statement cache yet.
DMAC currently screens at market cap $157.4M. GS currently screens at market cap $324.25B and trailing P/E 20.1.
Not investment advice. Open the DMAC and GS stock pages for the full models.
Not investment advice.